Lonax

Quick links to important sections

Lonax

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lonax

Quick Facts

Property Description
Active ingredient Lornoxicam
Form Tablets; Lyophilized powder for injection
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Pain management and inflammatory relief
Origin Synthetic oxicam derivative

What Type of Medicine is Lonax (Lornoxicam)?

Lonax is the trade name for the powerful, synthetic active compound Lornoxicam (INN), which is classified under the broad pharmacological umbrella of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This agent is classified under the Anatomical Therapeutic Chemical (ATC) code M01AC05 (Oxicams). Its distinctive chemical structure as an oxicam derivative sets it apart from non-oxicam NSAIDs.

Lornoxicam is a single-ingredient product whose fundamental pharmacological action involves its role as a potent, non-selective Cyclooxygenase (COX) inhibitor. The compound provides rapid and sustained analgesic and anti-inflammatory activity. Its mechanism involves the inhibition of prostaglandin synthesis, which is the basis for its established profile for analgesic efficacy. This means the medicine is clinically recognized for its ability to effectively block the chemical signals that cause pain and inflammation in the body.

Lonax: Defining its Forms and High-Level Purpose

The core purpose of Lonax is to provide effective pain management and alleviate the symptoms associated with inflammatory conditions. This general therapeutic benefit is a direct result of its mechanism, which reduces pain sensitivity and inflammation by interfering with the synthesis of key inflammatory mediators.

The medicine is supplied in two principal preparations that define its route of administration. The most common form is the oral tablet. Additionally, the drug is available as a sterile, lyophilized powder for injection, which is reconstituted into a solution immediately prior to use for parenteral administration. Lornoxicam, in its injectable form, is suitable for both intravenous (IV) and intramuscular (IM) use, allowing for flexible application when oral intake is not feasible. This dual format allows medical professionals the flexibility to administer the drug orally for continuous relief or by injection for faster, systemic action when a rapid response is necessary.

What side effects are possible with Lonax?

Lonax: Possible Side Effects and Safety Information

This summary provides a structured overview of the documented safety information for Lonax based on authoritative drug safety sources. Safety information for Lonax often relates to formulations containing either Lornoxicam (an NSAID) or Oxcarbazepine (an anticonvulsant), as the proprietary name may apply to different active ingredients globally. The reported adverse reactions and warnings vary significantly depending on the active compound.

Key Safety Considerations (General)

  • Serious Skin Reactions: For the Oxcarbazepine-containing formulation, rare but potentially life-threatening skin reactions, including Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported in regulatory literature. Immediate medical evaluation is necessary if a rash or signs of hypersensitivity develop.
  • Cardiovascular and Gastrointestinal Risk: For the Lornoxicam-containing formulation (an NSAID), there is a documented risk of serious gastrointestinal events, such as bleeding, ulceration, and perforation, as well as an elevated risk of blood clots, heart attack, and stroke, especially with prolonged use or in high doses.

Common and Serious Adverse Reactions

Classification Common Adverse Reactions (General Examples) Serious Adverse Reactions (Regulatory Examples)
Anticonvulsant Dizziness, drowsiness, nausea, headache, fatigue, unsteadiness, visual disturbances, tremors, low blood sodium levels. Severe hypersensitivity reactions (including rash, swelling, difficulty breathing), low blood sodium requiring hospitalization, blood disorders, suicidal thoughts or behavior.
NSAID Nausea, vomiting, diarrhea, indigestion, stomach pain, dizziness. Gastrointestinal bleeding, perforation, severe allergic reaction (anaphylaxis), kidney impairment, cardiotoxicity (e.g., heart attack, stroke).

Population-Specific Safety Notes

  • Pregnancy and Breastfeeding: Use of most Lonax formulations during pregnancy or breastfeeding is generally advised against or requires caution, as specific risks to the fetus or infant must be weighed against therapeutic benefits. Definitive evidence of risk, particularly in later stages of pregnancy (for NSAID-containing versions), necessitates consultation with a healthcare provider.
  • Hepatic and Renal Impairment: Caution is mandated for patients with existing kidney or liver disease, often requiring dose adjustments and regular monitoring of organ function, as per regulatory guidelines.

Overall Safety Profile

The official safety documentation for Lonax emphasizes that its risk profile is highly dependent on its specific active ingredient. This necessitates strict adherence to prescribed monitoring and clear awareness of the respective compound's serious adverse reactions, such as the potential for severe skin conditions with the anticonvulsant or significant cardiovascular/gastrointestinal toxicity with the NSAID. The regulatory safety structure highlights a need for individualized risk assessment, particularly in vulnerable populations.

Overdose and Emergency Response

If Lonax overdosage is suspected, regulatory authorities mandate that immediate medical attention be sought. The official label requires contacting emergency services or a Poison Control Center immediately for any suspected exposure.


Documented Overdose Manifestations

The documented clinical signs of overdosage most commonly include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. Neurological effects may also manifest, including dizziness, headache, and somnolence (drowsiness), as well as disturbances in vision or tinnitus (ringing in the ears).

Overdose is associated with the potential for severe or life-threatening outcomes. These documented severe manifestations include gastrointestinal bleeding and perforation, acute renal failure, hepatic dysfunction, and severe CNS symptoms such as cramps or convulsions. An increased risk of toxicity is noted for patients with pre-existing renal impairment and a reduced clearance rate is reported in the elderly.


Management and Antidote Information

The official regulatory profile states that no specific antidote is known for Lornoxicam overdosage. Management is required to be symptomatic and supportive. Following suspected ingestion, healthcare professionals may consider measures such as gastric lavage and the administration of activated charcoal. Close medical observation is required, with continuous monitoring of renal and hepatic function.

Therapeutic Uses of Lonax

What Lonax Treats: Main Uses and Benefits

Lonax (Lornoxicam) is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed, and is commonly used to help with symptoms related to inflammatory or irritative states. The medicine is utilized for managing symptoms associated with significant physical distress.

This medication is generally applied for conditions presenting with acute or recurrent episodes of pain and inflammation, including symptomatic relief in chronic conditions such as osteoarthritis and rheumatoid arthritis, as well as for short-term management of acute painful episodes like sciatica and postoperative pain following surgical procedures.

“It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.”

This use supports patients during difficult episodes, and assists with maintaining functional stability by easing the symptom load.


Quick Fact: Support for Musculoskeletal Symptom Management

Domain Focus Symptom Category Patient Benefit
Rheumatology Joint pain and stiffness Assists with maintaining functional stability
Acute Pain Inflammation and tenderness Contributes to easing the symptom load
Clinical Scenarios Postoperative discomfort May help patients cope more steadily with symptom fluctuations

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Lonax (Lornoxicam) is strictly defined by regulatory bodies to protect populations at increased risk, primarily focusing on pre-existing severe conditions, allergies, and age restrictions. Individuals who do not meet the official eligibility requirements must not use this medicine.


Contraindicated Populations (Must Not Use)

Area of Restriction Condition or Status
Hypersensitivity Known allergy to Lornoxicam or any other NSAIDs (e.g., aspirin).
Organ Function Severe hepatic, renal, or heart failure.
Gastrointestinal Active peptic ulceration, recurrent ulceration history, or active bleeding (GI or cerebrovascular).
Pregnancy Women in the third trimester of pregnancy.

Population Restrictions and Limitations

Population Group Official Regulatory Status
Pediatric Not recommended for use in children and adolescents under 18 years due to insufficient safety and efficacy data.
Reproductive Not recommended during the first two trimesters of pregnancy or while breastfeeding.
Elderly Use requires caution and monitoring, particularly concerning renal and hepatic function.
Organ Function Mild to moderate renal or hepatic impairment requires precaution and dose consideration.

These guidelines establish the regulatory boundaries for the drug's use, ensuring that specific, high-risk patient groups are formally excluded or treated with documented caution as outlined in authoritative prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents categorize Lornoxicam's interaction profile based on risks of toxicity and pharmacokinetic changes. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is advised to be avoided due to the increased potential for additive adverse effects.

Pharmacodynamic Interactions

The combination of Lornoxicam with Anticoagulants (e.g., Warfarin) or Platelet Aggregation Inhibitors may lead to an enhanced risk of bleeding and hemorrhage. Lornoxicam can also reduce the therapeutic effect of Antihypertensives (ACE inhibitors, ARBs, Diuretics). The co-administration with immunosuppressants like Ciclosporin or Tacrolimus is documented to increase the risk of nephrotoxicity; this interaction requires closer monitoring of renal function.

Pharmacokinetic and Exposure Alteration

Lornoxicam's metabolism involves the CYP2C9 enzyme pathway. Substances that inhibit this enzyme, such as Cimetidine, may officially lead to an increase in Lornoxicam plasma concentrations. Conversely, Lornoxicam may increase the plasma levels of co-administered medicines, including Lithium, Methotrexate, and Digoxin, which may increase the risk of adverse effects from those agents. Regulatory guidance also notes that the presence of food delays and reduces Lornoxicam absorption.

Mechanism of Action

How Lonax Works: The Mechanism of Action


Lonax exerts its action primarily as a non-selective inhibitor of the Cyclooxygenase ( COX) enzyme system, targeting both the COX-1 and COX-2 isoenzymes with comparable affinity. This fundamental molecular action blocks the enzymatic conversion of arachidonic acid, preventing the synthesis of key downstream mediators like Prostaglandins and Thromboxanes within the Arachidonic Acid Cascade.

Beyond COX inhibition, Lornoxicam exhibits a complementary inhibitory ability toward Inducible Nitric Oxide Synthase ( iNOS) and suppresses the formation of the pro-inflammatory cytokine Interleukin-6 ( IL-6). This multi-vector suppression profile contributes to a broader inhibition of the inflammatory biochemical process.

The resulting physiological cascade begins with the severe restriction of Prostaglandin E2 ( PGE2) at sites of tissue distress. This prevents the chemical sensitization of peripheral nociceptors (pain-sensing neurons). The physiological consequence is the reduction of peripheral nociceptive signaling and the suppression of localized tissue swelling, which is mediated by the rapid kinetics of enzyme inhibition.

Dosage and Administration Information

How Lonax is Used: Administration Guidelines

Lonax (Lornoxicam) is used according to specific guidelines that govern its administration route, dosage, and preparation. The medicine is available for oral intake as a tablet and as a lyophilized powder for solution for intravenous (IV) or intramuscular (IM) injection.


Dosing and Frequency

For adult patients, the total daily dose typically ranges from 8 mg to 16 mg, with a strict maximum daily limit of 16 mg. The oral formulation is generally administered in two or three divided doses per day and should be taken with sufficient liquid, usually before meals. Parenteral treatment is primarily intended for short-term therapy initiation, with a recommended single dose of 8 mg.


Administration and Population Rules

The injectable powder requires immediate reconstitution in the supplied solvent prior to use. IV administration must proceed over a minimum of 15 seconds, while IM administration requires a minimum of 5 seconds. The preparation is intended for single use only, and the needle must be changed following reconstitution to maintain sterility.

Special dosage restrictions apply to certain populations. Use is not recommended for children and adolescents under 18 years of age due to insufficient data. For patients with mild-to-moderate renal or hepatic impairment, the maximum daily dose is restricted to 12 mg in divided doses. General practice involves utilizing the lowest effective dose for the shortest duration necessary for symptomatic control.

Recent Clinical Evidence

Lonax: Recent Clinical Evidence

Evidence for Use in Moderately to Severely Active Crohn's Disease

Research for Lonax in Crohn's Disease (CD) mainly consists of short- to intermediate-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, and they included adult patients diagnosed with moderately to severely active CD. Research examined outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states, describing the specific outcomes (like symptom criteria and biomarker changes) the researchers monitored. Studies conducted during periods of increased symptom activity reported differences in the patterns observed in the treatment group compared to the placebo group regarding the proportion of patients who achieved specific criteria for clinical response and clinical remission during the initial, short-term treatment phase.

Evidence for Use in Acute Pain Due to Trauma

The evidence for Lonax in acute pain is based on short-term, placebo-controlled, double-blind RCTs. These trials were conducted in patient populations presenting with conditions associated with acute or disruptive episodes, specifically pain following minor trauma. Research examined outcomes related to physical discomfort, primarily measuring changes in the intensity of the patient's pain at brief intervals after administration. Studies also monitored the request for, and timing of, additional pain medication. Research describes patterns of measurement observed during the study period, including differences in the mean change of pain scores when comparing the Lonax group to the placebo group.

Long-Term Studies and Follow-Up Data

Long-term follow-up data for Lonax often comes from extended-duration phases of the initial trials. Research has explored the durability of the initial findings and monitored the patterns of clinical measurements in patients who stayed in the study and continued to receive the intervention. However, it is not yet clear whether the observed patterns are maintained long-term. The follow-up durations were limited in the core trials, and further research is ongoing to better characterize the long-term course.

Research in Special Populations

Research has explored Lonax in special populations, but the data are still emerging and may be insufficient for certain groups. The acute pain studies included patients 12 years and older, while the chronic condition RCTs focused primarily on adult patients (18 and older). Evidence is limited for groups such as pregnant patients, or those with complex co-occurring medical conditions. The findings describe group patterns, and research does not determine whether an individual in a less-studied subgroup will experience similar outcomes.

Research Gaps and What is Still Unknown About Lonax

The research contributes to the broader evidence landscape for Lonax, but key areas remain uncertain. Research highlights that long-term outcomes beyond the two-year timeframe of the core studies remain insufficiently characterized. Comparative evidence is lacking in some areas, particularly concerning direct research against all currently available established therapies. Research is ongoing to address these limitations.

Frequently Asked Questions (FAQ)

Common questions about Lonax (FAQ)


Q: Will taking Lonax affect my ability to drive or operate machinery?

Official product information indicates that Lonax may cause effects such as dizziness or vertigo. Individuals who experience these effects are typically advised not to drive or operate machinery. These warnings are based on the potential for reduced mental alertness and physical coordination.


Q: Are there specific food or beverages I need to avoid while taking Lonax?

Regulatory documents suggest avoiding alcohol intake during treatment, as alcohol consumption may increase the documented risk of gastrointestinal bleeding. Additionally, taking Lonax with food may delay and reduce the overall absorption of the active ingredient, lornoxicam. The official administration instructions specify taking the oral form before meals.


Q: What does official research say about the long-term use of Lonax?

Studies and official documentation state that long-term follow-up data from the core clinical trials for Lonax are limited. Outcomes related to using the medicine beyond a two-year timeframe remain insufficiently characterized. Continued research is currently ongoing to better define the long-term course of treatment.


Q: Does Lonax interact with common anti-anxiety or antidepressant drugs?

Official regulatory information indicates that Lonax is documented to interact with SSRIs (Selective Serotonin Reuptake Inhibitors), which are a common class of antidepressant. Taking these medicines together may increase the overall risk of gastrointestinal bleeding. The potential for other interactions in this class is a topic for discussion with a healthcare provider.


Q: Can Lonax affect my appetite?

Official safety documentation lists anorexia (loss of appetite) as an uncommon adverse effect. This means that while possible, this effect has been observed in less than 1 in 100 patients, but in more than 1 in 1000 patients, as noted in official product information.


Q: How does the brand name Lonax compare to its generic version, if one exists?

When a generic version of a medicine is approved by regulatory bodies, it must meet the standard of bioequivalence. This means the generic must demonstrate that it delivers the same amount of the active ingredient into the bloodstream at the same rate and to the same extent as the brand-name product.


Q: Does Lonax cause weight gain, or is that a common myth?

Regulatory documents list 'weight changes' as a documented undesirable effect of the medicine. This safety note encompasses the possibility of either weight gain or weight loss, although it is not listed among the more commonly reported side effects.


Q: Can Lonax cause changes in mood or sleep patterns?

Yes, changes in mood and sleep are documented as potential side effects. Official documents list both insomnia (difficulty sleeping) and depression among the uncommon adverse effects of Lonax.


Q: Can I take my regular vitamins or herbal supplements while using Lonax?

The active ingredient is metabolized through the CYP2C9 enzyme pathway in the body. Some vitamins and herbal supplements are known to interact with this enzyme, which could potentially alter the amount of lornoxicam present in the bloodstream. Discussing all supplements with a healthcare professional helps manage potential interactions.


Q: How long does it typically take to notice the full effect of Lonax?

Following oral intake, the active ingredient typically reaches its maximum concentration in the bloodstream after approximately 30 to 60 minutes. This measurement reflects the time required for the active ingredient to reach its measured peak concentration.


Q: How long am I usually expected to take Lonax for the condition?

Official regulatory guidance does not specify a fixed duration of use for Lonax. Instead, the guidance mandates utilizing the lowest effective dose for the shortest duration necessary to control symptoms, consistent with its pharmacological classification.


Q: What are the signs of an allergic reaction to Lonax, according to patient leaflets?

Patient leaflets advise looking for signs of a severe allergic reaction such as wheezing, chest tightness, or a severe skin rash. Other serious signs include sudden swelling around the face, lips, or throat that makes breathing difficult. These signs are documented as requiring prompt medical evaluation.


Q: Does Lonax contain any ingredients that might trigger a common allergy, like gluten or lactose?

Official product information confirms that the Lonax tablet formulation contains lactose monohydrate as a core excipient (inactive ingredient). Individuals with a known intolerance to lactose should be aware of this component. The formulation does not typically list gluten as an excipient.


Q: What is the guidance for taking Lonax if I have diabetes?

Official documentation notes a potential interaction with sulphonylureas, which are a class of medicine used to treat diabetes. This combination may increase the risk of a drop in blood sugar level, known as hypoglycemia. Close monitoring is typically recommended when taking both medications.


Q: What is meant by the 'bioequivalence' of Lonax's generic versions?

Bioequivalence is a regulatory standard used to compare a generic drug to its brand-name counterpart. It confirms that the generic is absorbed into the bloodstream at the same rate and to the same extent as the original product, ensuring comparable performance.


Q: What is the likelihood of developing tolerance to Lonax over time?

Studies monitoring the medicine's behavior in the body have indicated no evidence of accumulation of the active ingredient after repeated administrations. This finding is based on official drug monitoring data when the medicine is taken according to the recommended dosage.


Q: What are the documented effects of Lonax on fertility in men or women?

Official documentation states that the use of Lornoxicam, like other medicines in its class, may impair female fertility. For this reason, it is generally not recommended for women who are actively attempting to conceive.


Q: Does taking Lonax have any impact on blood test results?

Official safety documents indicate that taking Lonax has been associated with observed increases in blood urea nitrogen and creatinine levels. These are common laboratory markers that may be measured in blood tests, particularly those related to kidney function.

How should Lonax be stored and disposed of?

How to Store and Dispose of Lonax

Official regulatory guidelines mandate specific conditions to ensure the stability and safety of Lonax (Lornoxicam).


Storage Conditions

Lonax tablets must be stored at a temperature below 25 C or 30 C and kept in the outer carton to protect the medicine from both light and moisture. The product must be kept out of the sight and reach of children (P405) to prevent accidental ingestion.

Stability and Disposal

The injectable form must be used immediately after reconstitution from a microbiological perspective; chemical stability is limited to a short period (e.g., 24 hours at 2 C–8 C). Expired or unused Lonax must not be disposed of via household waste or wastewater. Instead, disposal must occur through a pharmacist or a designated take-back program in accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lonax found in:

A-Z Index: